Endo Pharmaceuticals

Endo Pharmaceuticals Inc. is an American pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet and Percodan. The new company was called Endo Pharmaceuticals Inc.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's May 31, 2012 filing.
Download all contributions to Endo Pharmaceuticals

  • Summary

    overview of the committee's finances
    Total Raised:
    $181,849
    Total Spent:
    $189,916
    Cash on Hand:
    $51,335
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Endo Pharmaceuticals Sources: OpenSecrets.org

Lobbying

$1,660,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Endo Pharmaceuticals

View all lobbying data for Endo Pharmaceuticals Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

7 Mentions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Endo Pharmaceuticals" in public comments on proposed federal regulations.

  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 FDA Make a determination that Opana® ER Tablets, 7.5 mg and 15 mg were not discontinued from sale for safety or effectiveness reasons - CLOSED 2011
    • Toggle 1 FDA To Determine Whether Talwin® Compound (Aspirin and Pentazocine Hydrochloride) Tablets, 325 mg/12.5 mg has Been Voluntarily Withdrawn or Withheld From Sale for Safety or Efficacy Reasons -CLOSED 2011
    • Toggle 1 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
    • Toggle 1 FDA Abbott requests that FDA Refrain from listing a TE rating for any drug approved under § 505 (b) (2) that references AndroGel unless and until it has conducted a notice-and-comment rulemaking 2011
    • Toggle 1 FTC Granting of Request for Early Termination of Waiting Period under Premerger Notification Rules 2011
    • Toggle 1 FMC Ocean Transportation Intermediary License Applicants 2011
    • Toggle 1 FDA Determine Whether Opana® ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 7.5 mg and 15 mg Have Been Voluntarily Withdrawn, Discontinued or Withheld From Sale for Safety or Efficacy Reasons - CLOSED 2011